Prostatype Genomics

Prostatype Genomics DSCR

The Debt Service Coverage Ratio (DSCR) of Prostatype Genomics (PROGEN.ST) as of Oct 22, 2026 is -4.49. In the previous year, Debt Service Coverage Ratio (DSCR) was -667.30 — a change of -99.33% (higher).

DSCR

-4.49

YoY

-99.33%

Last updated:

Debt Service Coverage Ratio (DSCR) of Prostatype Genomics is 2025 -4.49 . Debt Service Coverage Ratio (DSCR) of Prostatype Genomics was 2024 -667.30 . It decreases by -99.33% higher compared to the previous year.

The Prostatype Genomics DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2017
-0.60 SEK
Jan 1, 2018
-1.41 SEK
Jan 1, 2020
-10.03 SEK
Jan 1, 2021
-12.69 SEK
Jan 1, 2022
-31.94 SEK
Jan 1, 2023
-2.50 SEK
Jan 1, 2024
-667.30 SEK
Jan 1, 2025
-4.49 SEK
The Prostatype Genomics DSCR history
YEARDSCRYoY
-4.49-99.33%
-667.30+26,618.96%
-2.50-92.18%
-31.94+151.64%
-12.69+26.54%
-10.03+613.69%
-1.41+135.72%
-0.60-87.07%
-4.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Debt Service Coverage Ratio (DSCR) of Prostatype Genomics is -4.49 in 2025.

Debt Service Coverage Ratio (DSCR) of Prostatype Genomics changed from -667.30 to -4.49, representing a -99.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Prostatype Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Prostatype Genomics

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Prostatype Genomics